Search Technologies

The National Cancer Institute’s Laboratory of Cancer Biology and Genetics seeks partners to co-develop lentiviral plasmids, a research tool for visualizing and purifying cancer stem cells.

The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.

The National Institute of Child Health and Human Development (NICHD), Division of Intramural Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical samples with genetic mutations associated with endocrine tumors.

Researchers at NCI developed twelve lentiviral vectors that express both fluorescent and luminescent markers as a single fusion protein under various gene promoters.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Molecular Neurobiology seeks parties interested in licensing or collaborative research to further evaluate or commercialize specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice.

NIH scientists created and characterized an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials.The NCI seeks parties interested in licensing this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.

The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.

The National Cancer Institute Laboratory of Molecular Biology seeks parties to license or co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.